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WHAT THIS PAPER ADDS?
 The perioperative administration of heparin for the prevention of arterial thrombo-embolic complications during and after
reconstructive arterial surgery is widely advised and used. However, this systematic review did not ﬁnd sound scientiﬁc evidence
for the efﬁcacy of heparin in open and endovascular surgery for (ruptured) abdominal aortic aneurysm (AAA). On the contrary,
evidence was found indicating that heparin increases operation time, blood loss and blood transfusion requirements. The CAPPA
study group will promote a well-designed and properly conducted randomised controlled trial (RCT) to provide evidence on the
beneﬁts and risks of the use of heparin during AAA surgery.a r t i c l e i n f o
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Objective: Heparin is used worldwide by vascular surgeons as prophylaxis for arterial thrombo-embolic
complications during open and endovascular arterial surgery. Possible harmful effect of heparin use is
more perioperative blood loss, resulting in a higher morbidity and mortality. To evaluate the evidence for
the use of heparin during aorto-iliac arterial surgery a review was performed.
Methods: A systematic review was performed of literature from MEDLINE, EMBASE and Cochrane
databases, last search performed on March 8, 2012.
Results: For open surgery for abdominal aortic aneurysm (AAA), only 5 studies were eligible for review
and for endovascular aneurysm repair (EVAR) only 1 study. Overall methodological quality of the
included studies was poor. One randomised trial could be retrieved. Possible harmful effects of heparin
were found of increasing operation time, more blood loss and more transfusion requirements when
heparin was used for open AAA surgery in one study. No data were found comparing heparin to no
intervention for EVAR. One study compared heparin to a direct thrombin antagonist during EVAR,
showing no differences in clinical outcomes.
Conclusion: Despite limitations this review showed no compelling evidence on the beneﬁciary effect of
the prophylactic perioperative use of heparin during open surgery for (r)AAA. Authors will promote
a randomised controlled multi-center trial on this topic for elective open surgical repair of AAA.
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.tions on this paper, please go
þ31 229 257078.
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ciety for Vascular Surgery. PublisheEver since Murray in 19401 produced experimental and
(sparsely) clinical evidence that heparin could prevent thrombosis
during and after arterial reconstructions and embolectomies, local
or systemic perioperative heparinisation has been adapted world-
wide by vascular surgeons as a standard procedure to reduce per-
ioperative arterial thrombo-embolic complications (ATECs).d by Elsevier Ltd. All rights reserved.
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arterial reconstructive surgery were also soon recognised. Heparin
can increase peri- and post-operative bleeding and the need for
blood transfusions. The negative side effects of blood transfusions
are well recognised.2,3 Increased blood loss is also related to
a prolonged operation time, both independently enhancing infec-
tious complications resulting in increased morbidity and mortality.
Another factor complicating the prophylactic perioperative use
of heparin during arterial surgery is the unpredictable pharmaco-
kinetic response of individual patients. Heparin has no linear
doseeresponse and elimination curve after the administration of
a standard dose.4 This phenomenon is enhanced by the deregulated
coagulation cascade5,6 in vascular surgical patients. For this reason,
monitoring the level of anti-coagulation produced by heparin is
recommended.4,7 The preferredmethod is tomeasure the activated
clotting time (ACT), which correlates with the anti-thrombotic
effect of heparin better than the activated partial thromboplastin
time (APTT).8 Nevertheless, measuring heparin activity perioper-
atively has not gained widespread use.9
Since the introduction of heparin in 1940 only one randomised
controlled trial (RCT) has examined the beneﬁts of perioperative
prophylactic use of heparin in open surgery for abdominal aortic
aneurysm (AAA).10 Despite this lack of evidence, some guidelines
strongly advocate the use of heparin during open or endovascular
AAA surgery. In the 2008 American College of Chest Physicians
(ACCP) guidelines, Sobel et al.11 stated that level 1A evidence exists
for the intra-operative use of heparin for patients undergoing
vascular reconstructive surgery. The Society for Vascular Surgery
(SVS) guidelines for the care of patients with an AAA12 state that
heparinisation is used by almost all vascular surgeons, although no
references were supplied. Finally, the Society of Interventional
Radiology (SIR) stated in their recent Standards of Practice13 on
endovascular aneurysm repair (EVAR), “Although there are no trial
data regarding routine use of intra-operative heparin during EVAR,
the open surgical experience with heparinisation has been widely
applied to endograft procedures.”
Surveys on heparin use in the daily practice of vascular surgeons
and interventional radiologists have been performed throughout
Europe,14,15 the UK16e18 and the United States (US).9,19 They showed
wide variation in the prophylactic use of heparin (and protamine for
heparin reversal) perioperatively in reconstructive arterial surgery,
both for open and endovascular procedures.
We performed a systematic review and meta-analysis when
possible to assess the beneﬁcial and possibly harmful effects of
heparin or any other antithrombotic drug in open as well as in
endovascular aorto-iliac arterial surgery. We also investigated
whether other pharmaceuticals have been compared with heparin
(in randomised clinical trials (RCTs)) for open or endovascular
abdominal aorto-iliac arterial surgery.
Methods
This systematic review was performed in accordance with the
PRISMA 2009 (Preferred Reporting Items for Systematic reviews
and Meta-Analyses)20 and MOOSE (Meta-analysis Of Observational
Studies in Epidemiology Group)21 guidelines.
Search strategy
On 2 February, 2011, two independent investigators (AWand CB)
searched Medline (from January 1966 to February 2011) and
EMBASE (from January 1988 to February 2011) databases and the
Cochrane Database of Systematic Reviews (from 1990 to February
2011). The following combinations of medical subject headings
(MESH) were used: iliac aneurysm, Leriche syndrome, AAA,abdominal aorta, iliac artery, surgery, anti-coagulants or anti-
thrombotics. No ﬁlters or other restrictions were applied. By
cross-referencing the bibliographies cited in the included articles,
additional studies were identiﬁed and assessed for suitability. From
all of the studies identiﬁed in the search, the same independent
investigators selected potentially eligible studies according to the
information provided by titles and abstracts. Review of Materials &
Methods sections led to further exclusion of studies. Final inclusion
was performed after full-text review. Any disagreement between
the investigators was reconciled by a repeated review of the studies
in question until consensus was reached. The ﬂowchart for studies
on open AAA surgery is presented in Fig. 1. On 8 March 2012, the
same search was performed again, to capture any recent publica-
tions. The abovemethodwas followed in detail to search for articles
concerning EVAR and periprocedural use of anti-coagulants and/or
anti-thrombotics. To minimise the risk of missing any articles on
this subject, a separate MESH search was performed using the
extension ‘surgery or endovascular surgery’ in the above depicted
search strategy. No new hits were found.
Inclusion criteria
This review included RCTs and prospective and retrospective
case series on open or endovascular abdominal aorto-iliac arterial
reconstructive surgery (EVAR, endarterectomy, grafting procedures
or combinations) for both occlusive and aneurismal diseases.
Studies had to compare patient groups with and without intra-
operative arterial thrombosis prophylaxis or to compare heparin
prophylaxis with another anti-thrombotic agent. Reported
outcomes should include postoperative mortality, morbidity from
myocardial infarction (MI) or arterial thrombotic complications
(ATEC). Data on blood loss and blood transfusion requirements
during and immediately after the operation should be evaluated.
Only studies reported in English language were included.
Exclusion criteria
Reports with an unsuitable study design (e.g., dose ﬁnding
studies or lacking a group of patients without anti-thrombotic
prophylaxis) or with surrogate ‘end’ points (e.g., clotting time
after heparin administration) were excluded.
Methodological assessment
Two authors (AW and VJ) separately assessed the methodolog-
ical quality of the included articles. A checklist was used that
included the following items:
 Clear deﬁnition of study population?
 Sufﬁcient exclusion of selection bias?
 Method of intervention clearly described?
 Outcomes clearly described?
 Independent or blinded observers for data collection?
 Complete follow-up for hospital stay up to discharge?
 Detailed information on exclusion criteria and excluded
patients?
 Information on confounders available?
To further assess the quality of the selected studies, a system
was developed to score the study characteristics. Items recorded
from studies were: consecutive series of patients reported,
prospective or retrospective series, detailed information about
surgical procedure, details about heparin and protamine usage,
details on blood loss, detailed information on blood-transfusion
requirements and incidence of MI and ATEC. Differences in
Figure 1. Flowchart of literature search.
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Methodological quality of the study was not an exclusion criterion.
Data extraction
Data were extracted from eligible studies by two independent
authors (AW and VJ). AW extracted data from included studies
using a data extraction sheet, and VJ checked the extracted data.
Disagreement was followed by repeated review, and consensuswas
reached. Data were labelled as ‘no details’ if they were not reported
explicitly in text or tables. Two authors of included studies were
contacted by AW to provide further details that were not revealed
in the original publication.22,23
Standardisation of outcome measures
Mortality should preferably be deﬁned as mortality within 30
days of the operation. Morbidity from MI and ATEC should be re-
ported in the same time window as outcome measures. Mortality
was death by any cause. Morbidity from MI should preferably be
documented by an increase in cardiac enzymes in peripheral blood
samples and/or electrocardiography (ECG) changes or post-mortemﬁndings. ATEC was deﬁned as: any thrombosis or embolism in the
arterial vascular system during or after surgery that did or did not
require (surgical) intervention, including mesenteric ischaemia and
trash foot.
Statistical analysis
Continuous data were expressed as means and standard devi-
ations. For continuous outcomes, if mean values were not available,
medians were used. Relative risk with 95% conﬁdence interval was
calculated for dichotomous variables. Statistical analysis was per-
formed using IBM SPSS, version 19.
Results for Open AAA Surgery
Literature search
A total of 571 studies were identiﬁed, of which 502 publications
were excluded after evaluation of the title. The remaining 69 were
studied by evaluation of abstracts. Two duplicate studies were
excluded. No perioperative intervention was performed in two
studies, and no groups with and without heparin or other anti-
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abdominal vascular surgery was examined. No suitable end points
were reported in 23 studies. The remaining six articles were
studied by full-text analysis. It was then found that 3 studies did not
include groups with or without intervention. After adding two
articles from the reference list of the three remaining articles, ﬁve
studies met all criteria for inclusion. See Fig. 1 for ﬂowchart. Two
studies were performed in the UK; the other studies were per-
formed in Canada, Australia and the United States, respectively.
Characteristics of included studies
The selected reports were published between 1988 and 2008,
representing a total study population of 1491 patients. Data were
collected prospectively in three studies22,24,25 and retrospectively
in one study.26 One study concerned an RCT.10 In all studies, heparin
was administered intravenously before cross-clamping and results
were compared to a blank control group.
One study was designed as an RCT.10 In all studies intravenous
administration of heparin before cross-clamping was used and
results were compared to a blank control group. One study26
included 38 patients with aortic-iliac occlusive disease (AIOD)
and 161with aneurismal disease. The authors excluded the patients
with AIOD from evaluation, and we consequently excluded them
from this review. The four other studies included patients with
ruptured AAA (rAAA)24, elective AAA repair10,25 included elective
repair of AAA and both asymptomatic and symptomatic patients
with non-ruptured AAA.22
In all studies, blood loss and transfusion requirements were
assessed to evaluate whether increased bleeding occurred when
heparin was used. Overall mortality and incidence of non-fatal and
fatal MI for the heparin and the no-heparin groups was evaluated in
three studies.10,24,25 The incidence of ATEC could be retrieved from
four studies.10,24e26 Mortality details were reported as data within
30 days of the operation in three studies,10,22,24 details for MI and
ATEC within 30 days in two studies,10,24 one study26 provided the
in-hospital data and from one study26 no details could be retrieved
about the time relation between surgery and postoperative
mortality and morbidity. Main patient and study characteristics are
shown in Table 1.
Methodological quality
The results of the quality assessment and the checklist for
methodological quality are shown in Table 2. The overall method-
ological quality of the included studies was poor with only one
RCT.10 Selection bias was suspected in all other studies,22,24e26 and
in three studies a selective loss to follow-up could not be
excluded.22,25,26 None of the studies presented details about
exclusion criteria and excluded patients. A clear description of
confounders could not be retrieved from any of the studies. Only
one study25 offered adequate details about operative technique and
anti-thrombotic dosage. There was substantial clinical heteroge-
neity between studies, concerning both study populations and
interventions. This obstructed a sensible pooling of data.
Heparin and protamine
Neither the type nor manufacturer of heparin was speciﬁed in
any of the studies. The protocol for heparin administration varied
widely between the studies. In two studies,24,26 administration of
heparin depended on the surgeon’s preference. In the RCT10 the
options were local surgeon’s normal intra-operative heparin
regimen or no heparin at all. Using heparin selectively for multiple
pre-deﬁned reasons was the protocol in one study25 and in anotherstudy heparin was used according to local hospital protocol,22
which resulted in 85% of patients receiving heparin.
In all studies, heparin was administered intravenously (i.v.),
with a standard dosage of 5000 IU in three studies,10,24,25 irre-
spective of patient weight. One study22 did not give details about
dosage and in another26 5000, 7500 and >7500 IU were used
depending on the length of operation.
Heparin was administered before cross-clamping of the aorta in
four studies,10,22,24,26 with one study26 specifying administration of
heparin 3 min before cross-clamping. In one study25 heparin was
administered selectively after cross-clamping in 10 patients.
Repeated unspeciﬁed doses of heparin were given in one study “if
clotting became a problem during prolonged procedures.” 26
In four studies, protamine was used to reverse the effect of
heparin.10,22,25,26 In one study the standard dose of 5000 IU of
heparin was reversed with protamine 50 mg in all patients.25 If
post-reversal bleeding took ‘longer than expected’, the ACT was
measured and more protamine (usually 10 mg) was given. In two
other studies, the dose of protamine had to be sufﬁcient to reverse
one-half of the given heparin.10,26 In one of these studies, this
resulted in a standardised dose of 25 mg in only 13/145 patients
(9.0%)10 and in the other study protamine was given “in most
instances in a dose usually sufﬁcient to reverse one-half of the
administered heparin.”26 In some patients with short clamping
times the entire heparin dose was reversed. The two remaining
studies,22,24 did not give details on the use of protamine. In one
study “most often (at individual surgeon’s preference), protamine
was given after completion of the arterial reconstruction at a dose
of 50e100 mg, depending on the original dose of heparin. The use
of protamine was not APTT related.”22 (personal communication
AW and ﬁrst author).
Operative details
The abdominal aortawas cross-clamped above the renal arteries
in 45 patients (6.8%) in one study22 and in 38 patients (37%) in
another.25 When suprarenal clamping was indicated, heparin use
was mandatory.25 No differences in outcomes between heparin or
no-heparin groups and level of cross-clamping were found in these
studies. In the other three studies,10,24,26 the site of cross-clamping
was not speciﬁed.
In the study by Johnston et al.,22 the average cross-clamping
time of the abdominal aorta was 55  31 min. No differences in
outcomes could be identiﬁed between the heparinised and non-
heparinised groups related to clamp times. Clamp times over
70 min were associated with a higher incidence of postoperative
MI, but there was no difference in mortality. Furthermore, there
was no signiﬁcant difference in the incidence of cardiac events and
mortality between suprarenal and infrarenal clamping. The other
studies did not address the details of aortic cross-clamping time.
Thompson et al.10 reported slightly longer operation times in
heparinised patients compared to non-heparinised cases (120 vs.
105 min, p ¼ 0.06). Samson et al.,25 also found longer operation
times in heparinised patients than in non-heparinised patients
treated with tube grafts (median 150 vs. 132 min, p < 0.004).
Blood loss
Two subsets of patients showed a statistically signiﬁcant
difference for blood loss in favour of no-heparin usage (Table 3).
One subset constituted those treated with a tube graft in the study
by Samson et al.25 However, in this group operation time was
substantially less than in the group with heparinised patients with
tube grafts. Burnett et al.26 grouped their patients into three
operation time periods (<2.5 h, 2.5e3.5 h and>3.5 h) and analysed
Table 1
Main patient and study characteristics for open and endovascular AAA surgery.
Authors, Year Study design # of patients Male/Female Age in years
Chinien et al.
2008
rAAA
Prospective data collection
Jan. 1999eJan. 2004
Use of heparin up to surgeon’s preference.
131 hep þ: 78% / 22%
hep : 79% / 21%
79% / 21%
hep þ: 75 (median, 54e86)
hep e: 75 (median, 53e87)
Samson et al.
2002
Prospective data evaluation
Study period not stated.
Selective use of heparin.
249 86% / 14% 73 (median, 46e93)
Thompson et al.
1996
Randomised prospective multi-center trial
Study period not stated.
Randomized, sealed envelop.
Surgeon’s normal intraoperative heparin
or no-heparin.
284 hep þ: 82% / 18%
hep e: 88% / 12%
no details retrieved
Burnett et al.
1988
Retrospective data analysis
Jan 1984eJune 1986
2 surgeons using heparin, 1 no heparin
161 92% / 8% 66 (median, 56e88)
Johnston et al.
1988
Prospective data collection multi-center
March 1986eDec. 1986
Heparin use local hospital protocol.
666 80% / 20% 69.2 (mean, þ/e 7,7)
Total open AAA 1491
Stamler et al.
2009
EVAR
Prospective data collection
March 1994 e November 2006
Use of heparin or bivalirudin up to
interventionalist’ preference.
740 heparin: 88% / 12%
bivalirudin: 91% / 9%
90% / 10%
heparin: 75.7 (mean  7.7)
bivalirudin: 76.1 (mean  7.5)
Total EVAR 740
Authors, Year Type of disease Heparin þ/e Protamine use in heparin group
Chinien et al.
2008
rAAA
rAAA 63/68
Standard dose 5000 IU
No details
Samson et al.
2002
AAA 103/146
Standard dose 5000 IU
þ : 100%
Thompson et al.
1996
AAA 145/139
Standard dose 5000 IU
13/145 (9%)
Burnett et al.
1988
AAA 125/36
No details on dosage
5000 e > 7500 IU
þ : no details
“most instances”
Johnston et al.
1988
AAA 566/100
Dose not stated
þ : no details
“most often”
Total open AAA 1002/489
Stamler et al.
2009
EVAR
EVAR for AAA
elective
642/98
(heparin/bivalirudin)
None
A.M. Wiersema et al. / European Journal of Vascular and Endovascular Surgery 44 (2012) 359e367 363the relationship between blood loss and heparin dose. Categories
were 0, 5000 IU, 7500 IU and >7500 IU. Only for the shortest
operation time group (<2.5 h) could a meaningful comparison be
made. In this group, mean blood loss increased signiﬁcantly with
each increment of heparin (P < 0.05). Increased operation time,Table 2
The results of the quality assessment and the checklist for methodological quality for bo
Author Year Study
Population
No selection
bias
Method of
intervention
Description
outcomes
Chinien 2008 þ e þ/e þ
Samson 2002 þ e þ þ
Thompson 1996 þ þ e þ
Burnett 1988 þ/e e þ/e þ/e
Johnston 1988 þ e e e
Stamler 2009 þ e þ þ/e
Author Year Consecutive
series of pt.
Prospective
series of pt.
Surgery
details
Heparin
details
B
d
Chinien 2008 0 2 0 0 2
Samson 2002 0 1 2 1 2
Thompson 1996 0 2 1 0 2
Burnett 1988 2 1 0 1 2
Johnston 1988 2 2 1 0 1
Stamler 2009 2 0 2 2 2
0 ¼ no details retrieved from study, 1 ¼ incomplete details retrieved, 2 ¼ complete detahowever, was also signiﬁcantly associated with increased blood
loss for each heparin dose category (P< 0.05). In this study, heparin
increased blood loss signiﬁcantly (P < 0.05) in both the tube- and
bifurcated-graft group; heparin increased operation time only in
the tube-graft group.th open and endovascular AAA surgery.
of Independent
observers
No selective
loss to FU
Description of
confounders
Details on exclusion
criteria and
excluded patients
e e þ/e e
e e þ/e e
e þ þ/e þ/e
e þ þ/e e
e e e e
e þ þ/e e
lood loss
etails
Transfusion
details
Myocardial
infarction
ATE events
details
Total Score
(maximum ¼ 16)
1 2 2 9
2 2 2 12
2 2 2 11
0 0 1 7
1 0 0 7
2 0 1 11
ils retrieved.
Table 3
Results for open and endovascular AAA surgery.
Authors, Year Blood loss median
value heparin þ/e
Blood transfusion
details heparin þ/e
Chinien et al.
2008
rAAA
2000/2500 ml.
P ¼ NS
P ¼ NS, no further
details
Samson et al.
2002
Tubegraft:
1350/700 ml.
P < 0.004
P < 0.004
cell saver:
600/250 ml
P < 0.004
post-operation:
11.9% / 3.8%
Bifurcated graft:
1200/775 ml.
P ¼ NS
500/500 ml
P ¼ NS
11.4% / 6.3%
P ¼ NS
Thompson et al.
1996
1400/1500 ml.
P ¼ NS
3e6/4e6 units
P ¼ NS
Burnett et al.
1988
2270/280 ml.
(mean value)
P < 0.05
no details
Johnston et al.
1988
P ¼ NS
“no difference”
P ¼ NS
“no difference”
Blood loss:
retroperitoneal
bleeding/hematoma
heparin/ bivalirudin
Blood loss:
minor bleeding
heparin/bivalirudin
Blood loss:
major bleeding
heparin/bivalirudin
Blood transfusion:
PRBC
heparin/bivalirudin
Blood transfusion:
any
heparin/bivalirudin
Blood transfusion:
> 2
heparin/bivalirudin
Stamler et al.
2009
EVAR
0.3% / 1%
n ¼ 2/n ¼ 1
14% / 12%
n ¼ 90/ n ¼ 12
14% / 10%
n ¼ 91/n ¼ 10
12% / 16%
n ¼ 79/n ¼ 16
8% / 6%
n ¼ 50/n ¼ 6
11% / 13%
n ¼ 68/n ¼ 13
RR 3.28
(95% CI 0.29e36.52)
RR 0.87
(95% CI 0.46e1.66)
RR 0.72
(95% CI 0.36e1.44)
RR 1.33
(95% CI 0.74e2.39)
RR 0.79
(95% CI 0.33e1.89)
RR 1.25
(95% CI 0.66e2.36)
Authors, Year Overall mortality heparin þ/ Myocardial infarction (z) heparin þ/ Arterial thrombo-embolic complications heparin þ/
Chinien et al.
2008
rAAA
16% / 43% (*)
n ¼ 10/n ¼ 29
16% / 10% (*)
n ¼ 10/n ¼ 7
22% / 27% (*)
n ¼ 14/n ¼ 18
RR 0.37
(95% CI 0.16e0.85)
RR 1.54
(95% CI 0.55e4.33)
RR 0.84
(95% CI 0.38e1.87)
Samson et al.
2002
3.9% / 0.7% (z)
n ¼ 4/n ¼ 1
2.9% / 0% (z)
n ¼ 3/n ¼ 0
2.9% / 3.4% (z)
n ¼ 3/n ¼ 4
RR 5.67
(95% CI 0.62e51.49)
2.9 (95% CI 0.76e8.90)
0 (95% CI 0e3.2)
RR 1.06
(95% CI 0.23e4.84)
Thompson et al.
1996
4.1% / 7.9% (*)
n ¼ 6 /n ¼ 11
2.0% / 8.6% (*)
n ¼ 3/n ¼ 12
4.8% / 7.9% (*)
n ¼ 7/n ¼ 11
RR 0.52
(95% CI 0.19e1.45)
RR 0.24
(95% CI 0.07e0.87)
RR 0.61
(95% CI 0.23e1.62)
Burnett et al.
1988
No details retrieved No details retrieved 4.8% / 0%
n ¼ 6/n ¼ 0
4.8 (95% CI 1.97e10.60)
0 (95% CI 0e12,01)
Johnston et al.
1988
“No difference”
Total for heparin þ and : 4.8% (*)
“No difference” “No difference”
Overall mortality
heparin/bivalirudin
Myocardial infarction
heparin/bivalirudin
Arterial thrombo-embolic complications
heparin/bivalirudin
Stamler et al.
2009
EVAR
No statistically signiﬁcant difference
No details retrieved (*)
No statistically signiﬁcant difference
No details retrieved (*)
1.9% / 1% (*)
n ¼ 12/n ¼ 1
RR 0.79
(95% CI 0.10e6.17)
(z) ¼ fatal and non-fatal, (*) ¼ 30 days post-operative, (z) ¼ in hospital.
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in blood loss between heparinised and non-heparinised
patients.10,22,24 However, Chinien et al.24 encountered clinically
signiﬁcant blood loss (deﬁned as blood loss over 5000 ml) in only
one heparinised patient compared to 12 non-heparinised patients.
This counter-intuitive ﬁnding indicates selection bias in their
patients with rAAA, massively bleeding patients apparently being
spared of ill-advised heparin administration.
Transfusion requirements
Samson et al.25 found that the non-heparinised patients were
signiﬁcantly less likely to require cell-save and postoperative bloodtransfusions (P < 0.004) when a tube graft was implanted, but not
for bifurcated grafts (Table 3).
Three studies10,22,24 stated that no difference was found in the
transfusion requirements of heparinised and non-heparinised
patients, without providing detailed information. One study did
not mention transfusion requirements at all.26 Details on trans-
fusion requirements are depicted in Table 3.
Overall mortality
All-cause mortality is shown in Table 3. Chinien et al.24 found
a signiﬁcant difference in favour of heparin in the case of rAAA (16%
vs. 43%, relative risk (RR) 0.37, 95% conﬁdence interval (CI)
A.M. Wiersema et al. / European Journal of Vascular and Endovascular Surgery 44 (2012) 359e367 3650.16e0.85). This ﬁnding however is heavily biased by the fact that
haemodynamically unstable patients were cross-clamped as
quickly as possible, even before heparin could be given. Two studies
on elective AAA repair found no statistically signiﬁcant differences
in mortality.25,10 The other two studies did not report mortality at
all26 or did not report mortality separately for heparinised and non-
heparinised patients.22
It was learned from personal communication that intra-
operative heparin use did not inﬂuence mortality in the latter
study.22
Myocardial infarction
The overall incidence of MI is depicted in Table 3. Chinien et al.24
found fatal and non-fatal MI were diagnosed in 10 (16%) hepari-
nised patients compared to seven (10%) in non-heparinised
patients (RR 1.54, 95% CI 0.55e4.33). In the study by Samson
et al.25 three patients (2.9%) in the heparin group had a fatal MI,
while no MIs occurred in the no-heparin group. Thompson et al.10
reported that 1 patient (0.7%) in the heparin group and 4 (2.8%)
patients in the no-heparin group developed a non-fatal MI. Fatal MI
was diagnosed in 2 (1.4%) patients in the heparin group and in 8
(5.6%) patients in the no-heparin group (RR 0.24, 95% CI 0.05e1.15).
Combining fatal and non-fatal MI in both groups resulted in
a signiﬁcant difference (n¼ 3 vs. n¼ 12: RR 0.24, 95% CI 0.07e0.87)
in favour of the heparinised group. Thompson et al.10 commented
on this observed difference: “As this surprising result was seren-
dipitous and outside the original study design, no stratiﬁcation for
cardiac risk factors was available for analysis, but in view of the
large numbers in the two categories it is felt that the groups should
be comparable.” Two other studies did not provide details on MI
incidence. Johnston et al. did not observe differences in MI inci-
dence between heparinised and non-heparinised patients
(personal communication AW).
Arterial thrombo-embolic complications
Overall incidences of ATEC for all studies are shown in Table 3. In
the study by Chinien et al.,24 embolectomy after completion of
surgery was necessary in ﬁve patients (8%) from the heparin group
and in eight (12%) patients from the no-heparin group. When
patients who died intra-operatively were excluded, these ﬁgures
were 8% for the heparin group versus 14% for the no-heparin group.
Other ATECs in both groups were listed as: stroke (4), limb
ischaemia (5), bowel ischaemia (8) and paraplegia (2), all showing
no signiﬁcant difference between the heparin and the no-heparin
group (All ATECs: n ¼ 14 vs. n ¼ 18: RR 0.84, 95% CI 0.38e1.87).
In the study by Samson et al.,25 one non-heparinised patient
receiving a tube graft died 2 months after operation because of
colonic ischaemia and respiratory failure, and another non-
heparinised patient developed colonic ischaemia without necessi-
tating surgical treatment. In the heparin group, they found one
athero-embolic event that resolved spontaneously without tissue
loss. Distal embolectomy was performed in four patients, two from
the heparin group and two from the no-heparin group. In summary,
therewere three (2.9%) ATECs in the heparin group vs. four (2.7%) in
the no-heparin group (RR 1.06, 95% CI 0.23e4.84). In the study by
Thompson et al.,10 three (2.1%) patients from the heparin group
versus eight (5.8%) patients from the no-heparin group underwent
distal embolectomy (RR 0.36, 95% CI 0.09e1.39). Furthermore
athero-emboli, responding well to conservative treatment,
occurred in four and three patients in the heparin and no-heparin
group, respectively e total ATEC: n ¼ 7 vs. n ¼ 11, 4.8% vs. 7.9%
(RR 0.61, 95% CI 0.23e1.62). Burnett et al.26 reported that six (3.7%)
patients from the heparin group suffered distal ischaemic episodes:four cases of micro-embolic trash syndrome involving the feet,
treated conservatively, and twowith major vessel occlusion treated
with embolectomy. Johnston et al.22 stated in personal communi-
cation with no differences in ATEC for both groups.
Meta-analysis
A pooled meta-analysis of the above-described results was
considered not justiﬁed because of the quality of included studies,
heterogeneity in and between studies and detected bias towards
the use of heparin.
Results for Endovascular AAA Surgery
Literature search
We found no publications comparing outcomes after EVAR
between patients receiving perioperative arterial thrombosis
prophylaxis and patients who did not. One study compared
outcomes with heparin and bivalirudin (a direct thrombin antag-
onist) during EVAR.23
Characteristics of study
Details are listed in Table 1. The selected study was a retro-
spective analysis of a prospectively maintained database of 740
consecutive patients treated with elective EVAR for AAA between
March 1994 and November 2006 in the USA. Outcomes were
compared for 642 patients receiving UFH and 68 using bivalirudin.
Procedural outcomes were scored according to the reporting
standards for endovascular AAA repair.27 Major complications,
minor and major bleeding complications and the need for trans-
fusions were retrieved. Details on mortality and MI were not
reported.
Methodological quality
Details and score for study quality are shown in Table 2. No
randomisation was performed for heparin or bivalirudin. The
choice of anti-coagulant was left to the discretion of the inter-
ventionalist and no speciﬁc guidelines were supplied for this
choice, thereby creating selection bias. No detailed description of
confounders was retrieved from the article.
Heparin and bivalirudin
Heparin was administered i.v. as a bolus of 100 IU kg1 before
placement of an arterial sheath and bivalirudin i.v. as a bolus of
0.75 mg kg1 followed by continuous infusion of 1.75 mg kg1 h1
for the duration of the procedure. No (details on) measurements of
anti-coagulation values were depicted either for heparin or for
bivalirudin.
Operative details
Types of anaesthesia and arterial access differed for both
groups: 39 (39.8%) of patients from the bivalirudin group were
operated under general anaesthesia compared to 129 (20.1% from
the heparin group (RR 1.98, 95% CI 1.25e3.10). Some 48 patients
(49%) from the bivalirudin group and 462 (72%) from the heparin
group were operated on with regional anaesthesia (RR 0.68, 95% CI
0.44e1.05). Arterial access in the combination of cutdown/percu-
taneous was used in 12 (12.2%) of patients in the bivalirudin group
and in 238 (37.1%) from the heparin group (RR 0.33, 95% CI
0.18e0.62).
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There were no statistically signiﬁcant differences in bleeding
complications between both groups (Table 3).
Overall mortality and myocardial infarction
No details could be retrieved regarding in-hospital or 30-days
mortality. These patients are included in the major complications
grade 3. There was no statistically signiﬁcant difference in grade 3
complications between the heparin and bivalirudin groups: 4%
versus 2% (RR 0.5, 95% CI 0.12e2.14).
No details on fatal and non-fatal MI could be retrieved from the
article. These patients are included in major complications grade 1,
2 and 3. Only grade 1 complications occurred less often in the
bivalirudin group: 12.2% versus 25.1% (RR 0.49, 95% CI 0.26e0.92).
The deﬁnition of grade 1 cardiac complications is: little or no
haemodynamic consequences.
ATECs
Only 1 major complication could be attributed to ATEC in the
bivalirudin group (1.5%) compared to 12 in the heparin group (1.9%)
(RR 0.79, 95% CI 0.10e6.17).
Discussion
Since the introduction of heparin more than 70 years ago for
the “prevention of thrombosis when operation for repair of
blood vessels is undertaken,”1 this concept has never been
really challenged. Inventories concerning perioperative arterial
thrombosis prophylaxis in open reconstructive arterial surgery
showed a wide variety of regimens amongst vascular surgeons
throughout the world for the past 20 years.9,14e17 This variety
also exists for arterial endovascular procedures.18,19 To assess
the efﬁcacy of this prophylaxis in open or endovascular aorto-
iliac arterial surgery, the CAPPA study group from the
Netherlands performed a systematic review of the literature on
this subject.
For open aorto-iliac surgery, only ﬁve studies10,22,24e26 could be
included in this review. The overall methodological quality of the
included studies was poor. Only one RCT10 could be retrieved.
Clinical heterogeneity between studies was signiﬁcant, concerning
both studied populations and methods of intervention. All studies
used heparin as a prophylactic anti-thrombotic drug. Only two
studies reported detailed information about the use and dosage of
protamine for the reversal of heparin.10,25
Two studies25,26 reported signiﬁcantly more blood loss and
a longer operation time in heparinised patients treated with tube
grafts, and one of these studies26 found that blood loss increased
when heparin dosage increased. Statistically signiﬁcantly more
blood transfusions were needed in heparinised patients compared
to non-heparinised patents in one study.25
One study24 (on rAAA) reported a lower operative mortality in
heparinised patients (16% vs. 43%: RR 0.37, 95% CI 0.16e0.85). This
ﬁnding appears heavily biased because particularly unstable
patients ended up in the non-heparinised group because their
aortas were hurriedly cross-clamped before heparin could be
administered. In addition, senior registrars began operations in
these patients prior to the arrival of a consultant surgeon. These
facts readily could explain the signalled difference in mortality
between heparinised and non-heparinised patients in this study.
The other four studies10,22,25,26 did not report statistically signiﬁ-
cant differences between heparinised and non-heparinised
patients for non-fatal MI, fatal MI or operative mortality.However, in the RCT,10 the combination of fatal and non-fatal MIs
proved to be signiﬁcantly more frequent in non-heparinised
patients (8.6% vs. 2.0%: RR 0.24, 95% CI 0.07e0.87). This outcome
was, however, outside the original study design and the distribu-
tion of cardiac risk factors over both groups was unknown. There-
fore, this difference could result from over-presentation of patients
prone to cardiac ischaemia in the non-heparinised group.
Furthermore, this study excluded patients taking acetylsalicylic
acid (ASA), thereby excluding the cardio-protective effect of ASA
perioperatively. In all included studies, no statistically signiﬁcant
differences were found for the incidence of ATEC between heparin
and no-heparin groups.
A meta-analysis could not be justiﬁed, because of the quality of
the included studies, the detected heterogeneity in and between
studies and the bias found to be present in studies.
No studies comparing heparin with no-heparin were found in
the literature for EVAR nor studies comparing another anti-
thrombotic than heparin to a no-anti-thrombotic group of
patients. The only study that could be included was a retrospective,
non-randomised analysis of a small group (n ¼ 98) receiving
bivalirudin and a larger group (n ¼ 642) receiving periprocedural
heparin.23 No signiﬁcant reduction in bleeding complications or
blood transfusions was observed. Further, mortality and incidence
of MI and ATEC were not statistically signiﬁcant different. Thus,
a reduction of bleeding complications when using a direct
thrombin antagonist (bivalirudin) instead of heparin, as docu-
mented for coronary and peripheral endovascular procedures,28,29
could not be established for EVAR.
The present systematic review has several limitations. A small
number of studies were eligible for open AAA surgery and only one
for EVAR. Moreover the studies for open AAA surgery were pub-
lished over a time period of 20 years. In those 20 years, the peri-
operative care of vascular surgery patients has improved
considerably, resulting in better outcomes for AAA patients
undergoing surgery. For example, the introduction of statins and
the increased use of beta-blockers nowadays in the perioperative
period may inﬂuence the incidence of MI. The methodological
quality of the studies was poor, numbers of patients studied rela-
tively small and there was signiﬁcant clinical heterogeneity
between studies.
Despite these limitations this systematic review showed no
sound evidence on the beneﬁcial effect of the prophylactic peri-
operative use of heparin during open surgery for (r)AAA. This
review showed that possible harmful effects of increased opera-
tion time, more blood loss and greater transfusion requirements
when heparin was used in open surgery could be present. For
EVAR, no trial data could be found comparing heparin to no-
heparin. Despite promising results of direct thrombin antago-
nists in cardiovascular surgery and endovascular coronary- and
peripheral interventions, no studies could be found on these drugs
during open AAA surgery. During EVAR, a direct thrombin antag-
onist (bivalirudin) showed no clear beneﬁt compared to heparin in
one retrospective study. Since more evidence of the efﬁcacy and
safety of heparin is clearly needed, the CAPPA study group will
promote a multi-centre RCT evaluating the use of heparin versus
no-heparin and possibly versus a direct thrombin antagonist
before aortic cross-clamping in patients undergoing open elective
surgical repair of AAA. The hypothesis of such an RCT could be
a reduction of 30% of blood loss, a 50% reduction of blood trans-
fusion and a 50% reduction in bleeding-related wound complica-
tions. A power calculation based on these assumptions showed
that we would need 197 patients with open AAA repair in each
group (a ¼ 0.05 and b ¼ 0.10). For EVAR, a 50% reduction of blood
transfusion would require 85 patients per group for heparin or no-
heparin.
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